Opportunities and Risks

As a global enterprise with a diversified portfolio, the Bayer Group is exposed to a wide range of internal or external developments or events that could significantly impact the achievement of our financial and nonfinancial objectives.

Bayer regards opportunity and risk management as an integral part of corporate governance. Our risk management process and the opportunities / risks are outlined in detail in the Annual Report 2015 (Combined Management Report, Opportunities and Risks Report). There have been no material changes to Bayer’s overall risk situation. In addition to the risks described in the Annual Report, the following risk has existed since the third quarter of 2016: Should the acquisition of Monsanto fail to close due to antitrust law, we will be obligated to make a specified compensation payment to Monsanto (reverse antitrust break fee).

Moreover, further opportunities and risks may arise in connection with the expected acquisition of Monsanto.

No risks have been identified that could endanger the Bayer Group’s continued existence. There are also no risks with mutually reinforcing dependencies that could combine to endanger the Group’s continued existence.

Significant developments that have occurred in respect of the legal risks since publication of the Bayer Annual Report 2015 (Note [32] to the Consolidated Financial Statements) are described in the Notes to the Condensed Consolidated Interim Financial Statements under “Legal Risks.”